Assessing Ionis Pharmaceuticals (IONS) Valuation After A Strong 1 Year Shareholder Return [Yahoo! Finance]
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
GSK, Ionis claim study success for RNA-based hepatitis B drug [Yahoo! Finance]
GSK Reports 'Positive' Phase 3 Results From Chronic Hepatitis B Studies [Yahoo! Finance]
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B